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ABSTRACT 
Spinal tumor metastases are secondary tumors in the bone of the vertebral column 
that arise from primary cancers from other areas of the body. Metastatic neoplasms in the 
spine have significant implications for the overall quality of life of patients with all 
cancer types. Bone is one of the most common sites for metastases to develop, and the 
spine is the most common osseous site for metastatic disease. Accurate and early 
diagnosis is critical in order to prevent irreversible spinal cord damage. MRI is the 
standard for diagnostic imaging, and various techniques to employ key imaging findings 
are discussed. Treating spinal tumor metastases requires an interdisciplinary approach 
involving close collaboration between oncologists, neurosurgeons, radiologists and 
orthopedic surgeons. The Neurological, Oncological, Mechanical instability and 
Systemic disease (NOMS) decision-making framework has been developed to assess 
these four pillars in order to facilitate complex decision-making across specialties to 
improve treatment for secondary spinal tumors. One of the major advantages of NOMS is 
its ability to incorporate the most recent clinical data available in the decision framework. 
Each component of NOMS has various methods for standardizing prognostication and 
recommending treatment options, but the reliability of these methods is questioned by the 
literature. Standardized prognostication and treatment planning have high potential for 
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improving treatment outcomes, but more research on their accuracy is imperative for 
optimal application. Creating a common language across medical disciplines can help 
streamline the treatment process and prevent unnecessary complications. As the 
revolutionary advancements in cancer treatment continue to unfold and more cancer 
patients achieve long term survival, the incidence of spinal tumor metastases will 
increase for patients with advanced metastatic cancers. This thesis will discuss the utility 
of current diagnostic standards, assess the value of prognostic scoring systems, and 
evaluate the decision-making framework used to synthesize treatment recommendations 
based on diagnostic and prognostic data.  
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Metastatic spinal tumors are secondary tumors in the bone of the vertebral column 
that arise from primary cancers from other areas of the body. Metastatic neoplasms in the 
spine are highly prevalent and have significant implications for the overall quality of life 
of patients with all cancer types, as 20% to 40% of all cancer patients are affected by 
spinal metastases during the course of their treatment (Barzilai et al., 2018).  
Bone is one of the most common sites for metastases to develop, and the spine is 
the most common osseous site for metastatic disease (Boussios et al., 2018). Post-mortem 
analysis shows up to 70% of patients with malignant cancers have metastatic disease in 
the spinal column (Mossa-Basha et al., 2019).  This is due to the rich vascular supply and 
extensive lymphatic system in the bones of the vertebral column that allow for abundant 
access and nourishment of migrating metastatic cancer cells (Boussios et al., 2018). The 
most common primary cancers that spread to the spine are lung, prostate and breast, 
which also make up some of the most common types of cancer in the United States (Ge et 
al., 2019). In fact, 80% of patients with metastatic breast cancer develop bone metastases 
(Alpantaki et al., 2020).  
Spinal tumors are classified as either epidural (extradural) or intradural. Epidural 
tumors are the most common form of vertebral metastases, and they typically do not 
directly invade the spinal cord. These tumors form in the epidural space outside of the 
dura membrane protecting the spinal cord. Intradural tumors are less common and can be 
further subclassified as intramedullary or extramedullary (Ng et al., 2017). 
Extramedullary intradural tumors form inside the dura and may or may not involve the 
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spinal cord. Intramedullary intradural tumors are rare, and they form in the spinal cord 
matter itself which can lead to intractable pain or neurologic symptoms (Ng et al., 2017). 
This thesis will primarily focus on literature regarding epidural spinal tumors. 
In order to ascertain the clinical decision-making components that are used to 
develop treatment plans, this thesis will review the major literature findings regarding the 
diagnosis and prognostication of spinal tumor metastases. It will first explore the way 
metastatic vertebral tumors are diagnosed, and then analyze the prognostic tools used to 
assess indications for different treatment methods. 
 
Metastatic dissemination of primary tumors to bone and spine 
It is important to note that patients with spinal tumor metastases have already 
entered the later stages of their cancer, and it is essential for clinicians to consider the 
risks and comorbidities that are inevitably accompanied with these patients when 
developing treatment plans. Understanding the dissemination patterns of primary tumors 
that metastasize to the bones of the spinal column is therefore critical. 
Since the publication of Stephen Paget’s “seed and soil” hypothesis in The Lancet 
in 1889, it has been widely recognized that certain types of cancer show an organ-specific 
pattern of metastasis (Chambers et al., 2002). Paget’s “seed and soil” hypothesis 
describes the propensity of various types of cancer to form metastases in particular 
organs due to the “dependence of the seed on the soil,” where the cancer cells are the 
“seeds” that depend on the microenvironment of the secondary organ (the “soil”) in order 
to proliferate (Paget et al., 1889). This theory that certain primary cancers will 
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preferentially spread to specific visceral organs based on the characteristics of the 
secondary organ has since been contested; In the 1920s, James Ewing suggested that 
circulatory patterns between the primary tumor and secondary organs were sufficient to 
account for organ-specific metastases (Chambers et al., 2002).  
Recent studies support a combination of dependence on both circulatory patterns 
and the secondary organ characteristics. A series of autopsy studies documented larger 
than expected numbers of bone metastases from breast and prostate cancers based solely 
on blood-flow patterns (Weiss et al., 1992). The same study also found fewer numbers of 
skin metastases than expected based on blood-flow patterns for osteosarcomas, stomach, 
and testicular cancers (Weiss et al., 1992). Of the 16 primary tumor types and 8 target 
organs that were analyzed, metastasis in 66% of the tumor-type-organ pairs seem to be 
adequately explained on the basis of blood flow alone, whereas the remainder were found 
to be due to positive or negative interactions between cancer cells and the environment of 
the metastatic site (Weiss et al., 1992). These finding suggest a role for both circulatory 
and organ-environment factors.  
The precise mechanisms by which malignant tumors metastasize to specific 
secondary sites has been relatively unexplored (Budczies et al., 2014). A few more recent 
studies have attempted to assess cancer specific progression patterns of disease. Budczies 
et al. analyzed 16 major types of primary tumors in 6597 patient autopsies to identify 
common metastatic progression patterns of different solid tumor types (summarized in 
Figure 1). The most common secondary sites for metastases were the liver, non-regional 
lymph nodes, lungs, bones and pleura respectively. The researchers found that 79% of 
 
4 
patients with malignant breast cancer had metastasized to bone, in addition to liver 
(80%), non-regional lymph nodes (60%), lungs (54%) and pleura (52%). Prostate cancers 
were predominantly associated with metastatic spread to bone (91%), whereas less than 
50% had metastases in other anatomical sites.  This evidence shows significantly 
different cancer specific patterns of metastatic progression for secondary site 
involvement. Different types of cancer therefore preferentially metastasize to different 
organs. While cancers have entity-specific predilection sites for tumor expansion, the 
researchers also determined that these patterns are partially attributable to the anatomical 
structure of vessels and blood flow as the underlying prerequisite for metastatic spread, 





Figure 1. Metastatic progression from 16 primary sites to 20 secondary sites. OSS 
represents bone metastases. Circle size is proportional to the number of tumors. Orange 
circles refer to the number of metastases from a single primary site. Arrow width is 
proportional to the percentage of tumors that metastasize from a primary site to a 
secondary site. Red arrows refer to significant “enrichment” of metastatic route from a 
primary site to a secondary site, and green arrows refer to significant depletion. Figure 
taken from Budczies et al. 2014.   
 
6 
As bone is one of the most common sites for tumor metastases, it is important for 
future research to study the progression patterns of cancers that metastasize to the bones 
of the spinal column due to the associated risk of spinal involvement. Metastatic bone 
disease occurs in a multi-step process that involves invasion of the extracellular matrix at 
the primary site, entry into circulation, passive tumor cell arrest within the distal organ’s 
vascular network, extravasation into the perivascular space, colony formation and 
proliferation in the distal tissue (Onken et al., 2019). While various cancers show blood-
flow dependent patterns of dissemination to secondary loci in spinal bones, these patterns 
are believed to be largely independent of primary tumor type since no spine-mediated 
homing mechanisms have been identified (Onken et al., 2019). Distinct preferences for 
certain cancers to metastasize to bone still exhibit a uniform distribution pattern 
throughout various anatomical bone locations. Red bone marrow (RBM) specifically has 
been associated with more frequent metastatic manifestation due to its increased blood 
flow, presence of adhesion molecules, and abundance of growth factors (D’Oronzo et al., 
2019). RBM content in the vertebrae is relatively high, and varies along the vertebral 
column with the thoracic spine having the highest RBM content, followed by the lumbar 
spine and sacral spine respectively, and significantly lower RBM content in the cervical 
spine. Using RBM as a measure for blood flow, dissemination patterns of vertebral 
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metastasis have been found to be correlated with RBM content (Figure 2) (Onken et al., 
2019).  
Figure 2. Distribution of metastases to the spinal column based on primary tumor 
location. Red bone marrow content or respective spinal column sections is shown on the 
right. Figure taken from Onken et al. 2019.  
 
In a retrospective review of 506 patients treated for spinal tumor metastases, 
Onken et al. found that metastatic spine disease (MSD) occurred most frequently in the 
thoracic and lumbar spine, less frequently in the cervical spine, and rarely in the sacral 
spine. Spinal metastases occurred most often in patients with lung cancer (21%), prostate 
cancer (19%), breast cancer (12%), cancer of unknown primary (8%), and kidney cancer 
(7%).  “Diffuse MSD” involving the cervical, thoracic, lumbar and sacral spine at the 
same time was found most frequently in prostate cancer, followed by breast and lung 
cancer which each displayed diffuse MSD patterns half as frequently as in prostate 
cancer. Lung cancer was found to have the greatest tendency to metastasize to the spinal 
column, most often only affecting one spinal region at a time. The thoracic spine was the 
preferred site for metastases in all six cancer types that were investigated.  The 
researchers determined that the distribution patterns of bone metastases are similar 
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throughout all primary tumor types, and the spinal distribution patterns are proportional 
to the RBM content of each spinal region. These findings support a blood-flow dependent 
distribution of tumor cells rather than spine-specific homing mechanisms.  
The increased incidence of metastases in the thoracic and lumbar regions has been 
well documented in the literature (Muccauro et al., 2011). This is likely due to increased 
vascular perfusion and drainage in these regions. For example, there is evidence of a 
higher likelihood for cancer cells to settle in areas of the spine that have increased blood 
supply due to the presence of the Batson Venous Plexus (BVP) (Onken et al., 2019). The 
BVP is a system of veins located in the epidural space between the spinal column bone 
and the dura matter that has no valves to control blood flow in order to allow increased 
flow through the plexus when systemic blood pressure is increased (Muccauro et al., 
2011). The BVP drains deep pelvic veins and thoracic veins into an internal vertebral 
venous plexus of the cervical, thoracic and lumbar spine, corresponding to less frequent 
sacral metastases since there is no BVP in that segment (Onken et al., 2019).  Lung and 
breast cancers preferentially metastasize to the thoracic spine, which can be explained by 
direct drainage from the azygous vein into the BVP at the thoracic region (Muccauro et 
al., 2011). Prostate cancers tend to metastasize to the lumbar spine, which can also be 
explained by direct drainage of the pelvic plexus in the lumbar region (Muccauro et al., 
2011).  
Understanding metastatic dissemination patterns can also be used to predict 
unknown primary sites for patients whose symptoms manifest due to secondary tumors 
before their primary cancer type has been diagnosed (Budczies et al., 2014). 8% of 
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patients in the Onken et al. study did not have a primary tumor diagnosis. By the time of 
their MSD diagnosis, 85% of these patients had extra-spinal bone metastases, and 51% 
had tumors in the thoracic spine. Future research that maps out the clinical timeline of 
metastasis for various cancer types can help uncover primary cancer diagnoses through 
backward analysis. The spinal column is a known predilection site for bone metastases, 
and MSD predominantly manifests early in the clinical course of cancer (Onken et al., 
2019). In 49% of the patients evaluated by Onken et al., MSD was diagnosed within the 
first year of cancer diagnosis, and a second peak was observed in 14% of patient after 5 
years-post cancer diagnosis. Spinal metastases from lung cancer tended to manifest 
within the first year of diagnosis, whereas prostate cancer metastases in the spine 
manifested later on.  
 
Spinal Cord Compression 
The location of the spinal column and surrounding vital organs makes tumors in 
the vertebral bones especially debilitating. Spinal tumor metastases can cause axial pain, 
vertebral body fractures, radiculopathy and spinal cord compression (Mossa-Basha et al., 
2019). The associated pain and debilitation make palliative treatments a major concern in 
the literature. Metastatic spinal cord compression (MSCC) is defined as compression of 
the spinal cord or cord equina due to cancer invasion of the vertebrae that may cause 
neurological disability (Boussios et al., 2018). Epidural metastatic spinal cord 
compression occurs in 5%-10% of cancer patients (Ge et al., 2019), though the exact 
incidence of MSCC is unknown and likely underestimated by at least 15% as the 
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detection rate depends on admission to a hospital and correct diagnosis (Rasool et al., 
2016). MSCC is the initial manifestation of malignancy in up to 20% of cases, and 
patients with breast, lung or prostate cancer comprise 60% of cases (Boussios et al., 
2018).  
Though most spinal metastases are localized to the thoracic spine, the lumbar 
spine is most frequently involved in MSCC (Bousious et al., 2018). As tumor cells 
proliferate in the vertebral bone marrow, the vertebral bones begin to collapse as the mass 
expands. This can lead to vertebral body collapse and vertebral fractures, in addition to 
compression of the dural sac and root sleeves (Figure 3).  This potentiates further 
neurological damage by causing vascular compromise, vasogenic edema, and 





Figure 3. Vertebra partially collapsed by metastatic tumor. Image taken from 
SpineUniverse. 
 
Symptoms of MSCC range from pain and paresthesia, motor weakness, loss of 
sphincter control, and paralysis. Back pain is usually the earliest sign of MSCC, and over 
95% of patients have symptoms by the time of diagnosis (Boussios et al., 2018). Pain 
characteristics that predict an MSCC diagnosis include localization in the upper or mid 
spine, progressive discomfort, and aggravation from activities that increase pressure 
within the spinal canal (Boussios et al., 2018). Localized pain is the result of periosteal 
stretching and inflammation caused by tumor growth. The pain can also be mechanical 
(pain localized to one location) or radicular (pain that follows the path of spinal nerves). 
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Mechanical pain indicates spinal instability, and often occurs with translational 
movements or lying in supine or prone positions. Radicular pain may develop due to 
nerve root compression, and is usually followed by motor and sensory symptoms, as well 
as bladder dysfunction.  
Treatment for MSCC is usually palliative, as the majority of patients die within 
the first year of diagnosis (Boussios et al., 2018). If the MSCC is of recent onset with 
some preservation of neurological function, symptoms can be reversible. However, 
recovery is unlikely if vascular injury has caused infarction of the spinal cord from 
prolonged compression (Boussios et al., 2018).  Autonomic symptoms with bladder 
dysfunction, absence of sweating below the lesion, and orthostatic hypotension are 
associated with poorer prognosis (Boussios et al., 2018). Early diagnosis and treatment is 
critical, and MSCC is therefore considered an emergency. 
 
Current Standards of Care 
Historically, the primary approaches to treating spinal metastases have been 
surgical resection and radiotherapy. The goals of surgical interventions are to preserve 
the patients’ movement functionality and quality of life while limiting the negative 
effects of necessary surgical lesions (Mossa-Basha et al., 2019). The primary indications 
for a surgical approach are pain, neurological deficits and mechanical instability resulting 
from later stage spinal tumors (Alpantaki et al., 2020). Complete surgical resection has 
been associated with significant post-operative complications and poor long-term control 
of spinal malignancies (Boriani et al., 2016). Conventional external beam radiation 
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therapy has also been a standard of care (Mossa-Basha et al., 2019). However, the use of 
radiation therapy is limited by the amount of radiation that can be given without harming 
the nearby spinal cord (Mossa-Basha et al., 2019).  
Recent advancements in imaging and minimally-invasive surgical techniques 
have shown promise in improving patient quality of life while also reducing surgical 
morbidities.  Percutaneous procedures, such as kyphoplasty and vertebroplasty in 
particular, have been increasingly used with palliative success in less complicated 
patients (Jung et al., 2019). Stereotactic body radiotherapy (SBRT) is another more recent 
development that has been successful as an alternative to classical radiotherapy. Instead 
of having the patient’s entire spinal column in the radiation field, SBRT allows for the 
targeted delivery of high ablative doses of radiation to a specific vertebral volume. This 
targeted approach allows for a much higher dose of radiation to be given locally with 













SPECIFIC AIMS AND OBJECTIVES 
 
This thesis will evaluate the decision-making strategies used to develop treatment 
plans for patients with spinal tumor metastases. Specifically:  
1. It will discuss the current standards for diagnostic imaging and compare the utility 
of diagnostic information to indicate treatment needs 
2. It will assess the value of various prognostication methods used to determine the 
appropriateness of currently available treatment options, and evaluate a decision-
making framework used to synthesize treatment recommendations based on 
diagnostic and prognostic information 
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DIAGNOSING SPINAL TUMOR METASTASES 
Accurate and early diagnosis of spinal tumor metastases is critical in order to 
prevent irreversible spinal cord damage. In the case of MSCC, treatment within 24 hours 
after onset of neurological symptoms is crucial, as patients who have had no motor 
function for over 48 hours are unlikely to recover any function following treatment 
(Robson, 2014).  
Magnetic Resonance Imaging (MRI) is the go-to imaging method used to 
diagnose spinal tumor metastases, as it is more widely available than computed 
tomography (CT) imaging and MRI offers unparalleled visualization of the spinal column 
and cord. A minority of the literature recommends the use of CT imaging to supplement 
MRI findings, but CT imaging is not as readily available as MRI and is not justified for 
use in uncomplicated patients (Kato et al., 2015). MRI provides superior clarity of bone 
marrow infiltration, better characterization of the levels of tumor involvement in the 
spinal column, and can delineate potential spinal cord compression or soft tissue 
involvement (Park et al., 2019).  
For optimal visualization of spinal metastases, the literature recommends the use 
of T1-weighted images—which shows fluid as dark and tissue as bright—rather than T2-
weighted images, which show fluid as light and tissue as dark (Johnson et al., 2007). The 
American College of Radiology recommends MRI without contrast to evaluate patients 
with known malignancy, but they also state that contrast-enhanced MRI is useful for 
patients suspected of having epidural or intra-spinal metastatic disease (Park et al., 2019). 
Contrast-enhanced MRI increases the sensitivity and specificity of image findings, but 
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with the caveat of invasiveness, time constraints and cost.  Park et al. asked radiologists 
about the usefulness of using contrast-enhanced MRI to detect and characterize spinal 
metastases after viewing the images of patients with known malignancy first without 
contrast and then with contrast in a later session. They found that contrast was useful for 
discerning between metastatic and benign masses in 39-53% of the 124 cases reviewed. 
Spinal metastases may mimic or obscure normal red bone marrow or other benign lesions 
in unenhanced MR images, and contrast-enhanced MRI can help discriminate between 
benign and malignant bone marrow changes. Park et al. also found that the overall 
additional time required for using contrast was only 14 minutes, which diminishes the 
time-factor consideration for evaluating patients with spinal metastases in need of an 
immediate diagnosis. However, they also noted that contrast was less useful for patients 
with diffuse metastatic spinal disease in which T1-wieghted imaging was sufficient 
enough for diagnosis. The researchers found no clinical or radiological factors that could 
help predict whether or not contrast would be useful for certain patients before they 
undergo imaging, which makes their findings difficult to apply in a clinical setting that 
requires such patient-specific care planning.  They also did not discuss the usefulness of 
contrast in determining spinal cord compression, but Johnson et al. reported earlier that 
unenhanced T1-weighted images are sufficient for evaluation of possible cord 
compression.  
Since many patients commonly present with back pain as the first sign of 
malignant spinal disease, it is important to be able to quickly distinguish whether or not 
the back pain is caused by spinal metastases so that diagnosis and treatment can begin as 
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early as possible. When cancer cells reach the bone marrow of the vertebrae, they 
interfere with the normal bone marrow microenvironment and can influence developing 
osteoblasts and osteoclasts (Tsuzuki et al., 2016). This hinders normal bone remodeling 
and can lead to vertebral compression fractures as the tumors grow. 9-29% of patients 
with bone metastases develop pathological fractures (Tsuzuki et al., 2016), and 90% of 
those fractures require surgery (Mansoorinasab et al., 2018). Metastatic vertebral 
fractures (MVF) are commonly mistaken with osteoporotic vertebral fractures (OVF) 
(Kato et al., 2015), and these two types of vertebral fractures are the most common 
causes of nontraumatic fractures of the vertebrae (Arana et al., 2020).   
When patients present with back pain due to a nontraumatic vertebral fracture, 
spine imaging can be assessed by practitioners of various specialties. Arana et al. 
conducted a study to evaluate diagnostic agreement between specialties when diagnosing 
OVF versus MVF. Interobserver and intraobserver agreement were assessed for 25 
clinicians at 18 hospitals across 12 geographic locations. Clinician specialties included 
radiologists, radiation oncologists, orthopedic surgeons, and neurosurgeons. Experience 
with interpreting spine MRIs ranged from 4 to 35 years. The clinicians assessed MRI 
images from 203 patients with confirmed diagnoses of either MVF or OVF; they were 
then asked to make their own clinical diagnosis without knowing the patients’ true 
diagnosis. After assessing the image findings alone, readers were asked to state their 
diagnosis. The patient’s cancer history was then disclosed, and the readers were able to 
modify their diagnosis. Statistical values for agreement were categorized as “poor”, 
“slight”, “fair”, “moderate”, “substantial” or “almost perfect”.  
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Intraobserver agreement (agreement between the reference diagnosis established 
by biopsy or clinical follow-up and the reader’s diagnosis based on the same images) was 
substantial, and improved to almost perfect after the patient’s history was disclosed. 
Interobserver agreement (agreement between the diagnoses of different readers) in the 
diagnosis of MVF versus OVF was fair before the patient’s cancer history was disclosed, 
and it increased to moderate after the cancer history was disclosed. This highlights the 
challenge faced by clinicians in differentiating between OVF and MVF based on imaging 
findings alone. Readers being informed of a patient’s clinical history of cancer had no 
significant impact on diagnostic accuracy, but they changed their diagnosis in 69.5% of 
patients. No consistent differences were found among different specialties, and diagnostic 
accuracy was moderate regardless of years of professional experience. This implies that 
fair interobserver agreement and moderate diagnostic accuracy may be the best that can 
be expected using conventional MRI because images of MVF and OVF are often 
indistinguishable.  As a result, some experts have suggested the use of a standardized 
scoring system to assist in the differentiation between the two.  
MRI is a powerful tool in the differential diagnosis of OVF and MVF, especially 
since other imaging modalities are generally not considered if malignancy is not 
suspected in patients without a known cancer diagnosis. Key MRI finding used by 
orthopedic surgeons and radiologists to diagnose MVF compared to OVF are 
summarized in Table 1. Sung et al. reported that diffusion-weighted MR imaging, which 
measures the Brownian motion of water molecules and is more commonly used to detect 
ischemia, is useful to improve diagnostic accuracy in the differentiation between OVF 
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Table 1. Seven key MRI findings to diagnose MVF versus OVF. Table was adapted 
from Kato et al. 2015. 
 
Image Feature Image 
Type 
Key Findings 
Pattern of vertebral signal intensity 
change 
sagittal When the vertebral fracture is 
associated with complete 
replacement of normal bone 
marrow signal intensity, MVF 
is implied. A round area of 
intensity change indicates 
MVF, whereas a band-like 
pattern indicates OVF. 
Cleft formation (“fluid sign”) sagittal A homogenously low intensity 
area in T1-weighted imaging 
and high intensity T2 imaging 
in the area of the fractured 
vertebra is known as a vertebral 
cleft or fluid sign. Presence of a 
fluid sign indicates OVF over 
MVF.  
Pedicle involvement sagittal Signal intensity change 
extending to the posterior half 
of the pedicle implies MVF. 
Contour of the posterior wall border sagittal A diffusely convex border or 
smoothly blunt protrusion pf the 
posterior wall border indicates 
MVF. “Focal bony 
retropulsion” with a sharp edge 
indicates OVF. 
Asymmetry of signal intensity change axial Symmetrical signal intensity 
change indicates OVF, whereas 
asymmetry indicates MVF.  
Pattern of posterior wall protrusion axial A single-peaked protrusion can 
be either MVF or OVF, but two 
peaks indicates MVF. 
Paravertebral mass axial A paravertebral mass con 
sometimes be seen in OVF, but 
is much more common in MVF. 
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and MVF especially for less experienced radiologists. Although the use of more 
advanced MRI techniques such as diffusion-weighted or contrast-enhanced MRI can be 
useful, the implications of these techniques in clinical practice remains controversial and 
inconsistent (Kato et al., 2015). To facilitate the accurate diagnosis between OVF and 
MVF, Kato et al. developed a scoring system to diagnose MVF by integrating several 
unenhanced MR images. They used discriminant analysis—a method used in pattern 
recognition to find a combination of features that characterize two classes of entities—to 
develop the MRI Evaluation Totalizing Assessment (META). A summary of the META 
scoring system is shown in Table 2. A total score less than or equal to 4 indicates OVF, 
whereas a total score greater than or equal to 5 indicates MVF.  
Kato et at. reported almost perfect agreement between the medical professionals 
used to test the META score they developed, but later studies have shown these results 
not to be reproducible (Arana et al., 2020). Urrutia et al. found overall poor interobserver 
and intraobserver agreement when testing the use of the META score with experienced 
spine surgeons and orthopedic surgery residents. Interobserver agreement was calculated 
by comparing the initial responses of all the evaluators, and intraobserver agreement was 
calculated by comparing the same rater’s responses between two evaluations of the same 
cases presented 3 months apart. The more experienced spine surgeons had significantly 
better interobserver agreement than the residents, but still had poor intraobserver 
agreement. They also reported insufficient diagnostic accuracy of MVF or OVF with 
only 57.81% accuracy for experienced surgeons and 51.28% for residents. This casts 
doubt on the effective clinical use of the META score in practice.  
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Table 2. META scoring system. Scores from each section are added together to 
comprise a final score that indicated MVF or OVF. Table taken from Kato et al. 2015. 
 
 
The conflicting findings regarding the usefulness of the META scoring system 
may be partially explained by the differences in participants used in each study. Kato et 
al. tested the META score using just two orthopedic surgeons that were part of the group 
that developed the score. On the other hand, Urrutia et al. had 6 orthopedic surgeon 
participants of various experience levels who did not have previous experience with the 
META scoring system. These small sample sizes of participants with drastically different 
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experience with the scoring system make it difficult to ascertain the true value of the 
prediction model. Although Arana et al. did not use any scoring systems in their study to 
evaluate agreement, they did assess the same MRI finding used to calculate the META 
score, and used a much larger and more diverse group of participants with varying levels 
of experience across different specialties. They concluded that the MRI predictors used 
together with patient history were inadequate based on relatively low agreement findings 
in addition to the low reproducibility of imaging findings reported by Kato et al. They 
cast doubt on the reliability of using evidence-based decision support systems for 
differential diagnosis in routine clinical practice.   
In contrast to discriminant analysis, which was used by Kato et al. to develop the 
META scoring system, Thawait et al. evaluated four other prediction models to predict 
vertebral compression fracture risk. They compared logistic regression, support vector 
machine, neural network, and classification tree prediction models. Logistic regression 
predicts the probability of an outcome as a function of independent variables by 
quantifying odds ratios associated with each variable, and it is extensively used in 
medicine because it is easily interpreted. Neural network is a nonlinear statistical tool 
used to model complex relationships between inputs and outputs or to find patterns in 
data, and it is able to identify multidimensional relationships that may not be apparent by 
other models. The support vector machine algorithm is a machine learning tool that offers 
solutions for both classification and regression problems, and assigns new inputs to 
defined categories. Classification trees are used to predict membership of cases in the 
classes of a categorical dependent variable from their measurements on one or more 
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predictor variables and are able to handle nonlinear relationships. All four models 
performed similarly in overall discrimination power, and no significant difference 
between any two models was found by the researchers. Based on their statistical analysis, 
logistical regression performed the best for diagnostic value. Several studies have 
attempted to develop a prediction model for MVF using logistical regression, but logistic 
regression is used to predict pathogenesis from risk factors, and its ability to discriminate 
between preexisting but undiagnosed conditions in controversial (Kato et al., 2015).  
While there is clearly need for an accurate and quantifiable way to better diagnose 
metastatic spinal disease, the current literature suggests that the available prediction 
models are not reliable enough to be used in a real clinical setting with patients yet to be 
diagnosed. The severity of the consequences for patients with spinal tumor metastases 
that are misdiagnosed, or delayed being diagnosed, requires prediction models to be 
significantly more accurate before they can be put to practice in a clinical setting. In order 
to successfully develop such a model, more larger scale research should be done on both 
prediction algorithms and the MRI image predictors themselves. While the findings that 
clinicians look for to diagnose spinal tumor metastases or metastatic vertebral fractures 
are relatively standard, their usefulness as objective predictors in an algorithmic model 
may not be equally reliable in different clinical settings. 
 
PROGNOSTICATION AND TREATMENT PLANNING FRAMEWORK 
 The treatment of spinal tumor metastases requires an interdisciplinary approach 
involving various clinical specialties to develop an effective, patient-specific treatment 
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plan. This often involves close collaboration between oncologists, neurosurgeons, 
radiologists and orthopedic surgeons. In order to facilitate complex decision-making in 
the treatment of secondary spine tumors, the interdisciplinary spine team at Memorial 
Sloan-Kettering Cancer Center has developed and used a decision framework called 
NOMS (Laufer et al., 2013). NOMS is based on four sentinel decision-making 
parameters: the neurological assessment, oncological assessment, mechanical instability 
assessment, and systemic disease assessment. A commonly referenced diagram of NOMS 
is shown in Figure 4. This provides physicians with a comprehensive decision framework 
in a common language across specialties to foster individualized patient treatment plans 
based on predicted outcome analysis.  
One of the major advantages of using the NOMS framework is that it is dynamic 
and incorporates updates on the most recent clinical findings that are shown to 
successfully improve patient outcomes (Barzilai et al, 2017). For example, new 
advancements in radiation therapy and interventional radiology, such as spinal 
stereotactic radiosurgery (SSRS) and percutaneous spine stabilization, have been 
incorporated into treatment recommendations as increasing research on their utility has 
become available (Barzilai et al, 2017).  There have not been any studies published to 
date that have statistically evaluated the effectiveness of using NOMS, but it is frequently 
used in literature research and is generally accepted as a useful tool in the spine oncology 
discipline (Barzilai et al., 2019). This thesis will now discuss each of the four pillars of 
NOMS and evaluate the validity of prognostic measures used in the NOMS framework to 
inform treatment decisions.  
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Figure 4. Schematic depiction of the NOMS decision framework. cEBRT is 
conventional external beam radiation. SRS is stereotactic radiosurgery. Stabilization can 




 The neurological and oncological assessments in NOMS are considered together 
by clinicians to help assess the implications for surgery or radiotherapy. The neurological 
assessment evaluates the degree of spinal cord compromise, primarily focusing on 
radiographic evidence of epidural spinal cord compression (ESCC). As mentioned earlier, 
metastatic spinal cord compression can cause severe neurological disability, and “high-
grade” ESCC is used as an indication for surgery (Bilsky et al., 2010). ESCC is 
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radiographically defined as an epidural metastatic lesion causing displacement of the 
spinal cord from its normal position in the spinal canal (Quraishi et al., 2015). 
 In NOMS, the degree of ESCC is quantified using an ESCC scoring system 
developed by Bilsky et al. in 2010 to help define “high-grade” ESCC. Before the scoring 
system created by Bilsky was validated by the Spine Oncology Study Group (SOSG), 
there was no clear consensus on the definition of “high-grade” ESCC in the literature. 
The ESCC score is a six-point grading system, shown as a schematic representation in 
Figure 5. Grade 0 indicates vertebral bone involvement only, grade 1a indicates epidural 
impingement without deformation of the thecal sac, grade 1b indicates deformation of the 
thecal sac without spinal cord abutment, grade 1c indicates deformation of the thecal sac 
with spinal cord abutment but no spinal cord compression, grade 2 indicates spinal cord 
compression with CSF visible around the cord, and grade 3 indicates spinal cord 
compression with no CSF visible around the cord (Bilsky et al., 2010). “High-grade” 
ESCC was thereby defined as grade 2 or grade 3 in the ESCC scale (Bilsky et al., 2010).  
 
Figure 5. Schematic representation of the 6-point ESCC grading scale. Figure taken 
from Bilsky et al. 2010.  
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Bilsky et al. validated their proposed scoring system by administering a survey to 
7 members of the SOSG. The participants consisted of neurosurgeons and orthopedic 
surgeons who specialize in treating spine tumors, and they were given radiographic 
images of 25 metastatic tumors to evaluate. They found that interobserver reliability of 
the ESCC grading scale ranged between fair and good, and intraobserver reliability 
ranged from good to excellent.  While these findings indicated suitable reliability for the 
scoring system, the small sample size of experienced spine surgeons calls into question 
the external validity of their results when applied to a broader, multidisciplinary clinical 
setting. To assess the significance of these downfalls, Arana et al. conducted their own 
study in a larger sample of 83 clinicians from various specialties and experience levels. 
Regarding the ability for clinicians to identify spine levels showing presence of ESCC 
from radiology images, both intraobserver and interobserver agreements were found to be 
substantial. They also reported almost perfect intraobserver agreement in calculating the 
ESCC score, as well as substantial interobserver agreement. This supports Bilsky’s 
conclusion that the ESCC score is reliable, and further suggest that the score can be 
useful to ensure accurate communication among multidisciplinary team members with 
varying levels of experience. Interestingly, all of the patients who had ESCC grades of 2 
or 3, and therefore required urgent clinical management, were correctly identified by the 
clinicians in the Arana et al. study. This is a reassuring example of how a standardized 
scoring system can prevent treatment delays due to clinician disagreement for patients in 
need of immediate care.    
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 The NOMS framework suggests that surgery is justified for certain patients with 
high-grade ESCC scores of 2 or 3, whereas patients with grades 0-1c would be 
considered for radiation therapy (Cofano et al., 2020). However, other studies have found 
inconsistencies with regard to specific ESCC grades and outcomes from recommended 
treatments. Quraishi et al., evaluated outcomes of surgical decompression in patients with 
different ESCC grades by comparing 2 groups of patients: group 1 consisted of low 
ESCC grades of 0-1c, and group 2 consisted of high grades of compression with ESCC 
scores of 2 or 3. They found no statistically significant differences in postoperative 
neurological outcomes between the two groups. This suggests that ESCC scores may not 
be entirely useful to differentiate surgical indications for decompression. Of the 40 
patients in studied in group 1, 7 showed neurological improvement after surgery, 29 
showed no change and 4 exhibited neurological deterioration. Of the 61 patients in Group 
2, 20 patients had neurological improvement, 37 had no change and 4 experienced 
neurological deterioration. While these differences were not statistically significant, 
Quraishi et al. concluded that the greater proportion of patients with higher ESCC scores 
that showed postoperative improvement justifies surgical decompression in this cohort. 
The only statistically significant differences found in this study were that patients in the 
low compression group were more likely to have had received chemotherapy prior to 
surgery, which identifies and important consideration for treatment planning since 
chemotherapy may reduce the ability for patients to tolerate surgery. On the other hand, 
the researchers did note that patients with higher degrees of spinal cord compression had 
more surgical complications. Other studies have also found no significant association 
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between ESCC score and neurological outcomes in patients treated with surgery or 
radiotherapy (Maseda et al., 2019). One study found no significant difference in 
postoperative survival time between high-grade and low-grade ESCC scores in patients 
that underwent minimally invasive percutaneous spine stabilization, but reported 
significant differences in postoperative neurological improvement between the two 
groups (Uei et al., 2018).  
 One of the most severe neurological consequences of spinal metastases is 
paralysis, which can be due to spinal cord compression or spinal instability (Uei et al., 
2018). Paralysis in cases of metastatic spine tumors can progress rapidly, and prompt 
treatment decisions are necessary to avoid severe conditions. Uei et al. investigated the 
severity and progression of paralysis with respect to the level of spinal cord compression 
using the ESCC scale. There was no statistical correlation between the severity paralysis 
and ESCC score. This can potentially be explained by how the ESCC grading system is 
based on T2-weighted MRI findings, but MRI finding of spinal cord compression useful 
to determine the severity of paralysis (Uei et al., 2018). Of the 467 patients analyzed, at 
least 50% of the patients with ESCC grade 1b or worse at the C1-T2 spinal levels 
developed some form of paralysis, and at least 50% of the patients with ESCC grade 1c 
or worse at the T3-L5 levels developed paralysis. Patients that exhibited anterolateral or 
circumferential ESCC of grade 2 or 3 at the C7-T2, T11-L1, or T3-T10 level 
demonstrated a paraplegia incidence of at least 30% within the first 3 weeks after MRI; 
these patients were determined to be the high-risk group for deterioration of paralysis. 
The different risk levels for paralysis in patients with different degrees of ESCC are 
 
30 
likely caused by factors associated with the location of the tumors in the cervical or 
thoracic region rather than the degree of ESCC alone.  
The ESCC scoring system accounts for the degree of spinal compression, but it 
does not take the axial localization or anatomical spinal level of the tumor into account 
(Maseda et al., 2019). To mitigate this, Maseda et al. incorporated 4 additional categories 
based on transverse localization in their study on neurological outcomes after treatment in 
patients with impending paralysis due to ESCC. The categories, depicted in Figure 6, 
included anterior compression alone, anterior and posterior compression, anterior and 
foraminal compression, and circumferential compression. They found that incidence of 
paralysis was higher in cases of ESCC grade 1c or worse with anterior and foraminal 
compression, as well as circumferential compression. Therefore, including the location in 
the spine and axial localization can help improve the ESCC score’s utility in determining 
risk for paralysis and surgical indications. 
 
Figure 6. Transverse localization of metastatic spine tumors. From left to right, A 
depicts anterior compression alone, AP depicts anterior and posterior compression, AF 
depicts anterior and foraminal compression, and APF depicts circumferential 
compression (anterior, posterior and foraminal compression together). Figure taken from 




The discrimination of treatment recommendations between ESCC cores of 1c and 
2 is another point of controversy in the literature. The discrimination between grade 1c 
and grade 2 can be difficult to determine on MRI due to the thinness of the layer of CSF, 
and certain cases of ESCC grade 1c may be too close to the spine to perform safe 
radiotherapy (Cofano et al., 2020). In the original publication of the ESCC scoring 
system, Bilsky et al. noted that a tumor presenting as an ESCC grade of 1c with actual 
spinal cord abutment presents significantly greater challenges in radiation planning and 
delivery than a grade of 1a or 1b which would have a 1-2mm distance from the spinal 
cord. Uei et al. conducted a follow up study on their research on neurological outcomes 
discussed above, and separated their two groups of comparison by ESCC scores of 2 or 
milder (group 1) and ESCC scores of 3 (group 2). In this new study, they demonstrated 
that improvement after treatment was significantly favorable in group 1 compared to 
group 2. Taking this together with the findings from Quraishi et al. in which there was no 
significant difference between groups split from grades 0-1c and 2-3, treatment 
recommendations for patients with ESCC grade 1c should likely be closer to those 
recommended for grade 2. Incorporating axial localization into the scoring system may 
also help improve the specificity of the score, and assist in pinpointing treatment plans 
for patients with spinal cord compression with less clear MRI findings on degree of 







 The oncological assessment is the responsiveness of the primary cancer type to 
currently available treatments, specifically radiation as it is the most effective and least 
invasive treatment for local tumor control at present (Laufer et al., 2013). Most of the 
oncological assessment is the determination of radiation sensitivity based on the primary 
tumor histology. Tumors are considered to be radiosensitive or radioresistant based on 
their response to conventional external beam radiation (cEBRT) (Barzilai et al., 2017). 
Moderate to highly radiosensitive tumors include most hematologic malignancies, as well 
as breast cancer, prostate cancer, ovarian cancer, neuroendocrine carcinomas and 
seminoma (Rades et al., 2006). Radioresistant tumors include most solid tumors, such as 
renal cell carcinoma, colon cancer, nonsmall cell lung carcinoma, thyroid cancer, 
hepatocellular carcinoma, melanoma and sarcoma (Mizumoto et al., 2011). The recent 
development of SSRS as an alternative treatment to cEBRT have shown success in 
treating spinal metastases in historically radioresistant tumor histologies (Yamada et al., 
2017).  
 
Mechanical Instability Assessment 
 Mechanical instability is an independent indication for surgical or percutaneous 
stabilization, as patients with spinal instability may require stabilization regardless of 
spinal cord compression grade or radiosensitivity of the tumor (Laufer et al., 2013). The 
Spine Oncology Study Group defines spinal instability as “loss of spinal integrity as a 
result of a neoplastic process that is associated with movement-related pain, symptomatic 
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or progressive deformity, and/or neural compromise under physiologic loads” (Laufer et 
al., 2013).  
Spinal instability is assessed using the Spine Instability Neoplastic Score (SINS), 
which was developed by the SOSG in 2010. They created the scoring system by a 
modified Delphi process, which is a method of group communication among a panel of 
geographically dispersed experts. The Delphi method was used to collect and distill 
decision-making knowledge from the 30 international spine oncology experts in the 
SOSG by means of questionnaires interspersed with controlled opinion feedback (Fisher 
et al., 2010). SINS is composed of 6 parameters, described in Table 3, and was deigned to 
estimate the degree of instability and indicate the necessity for immediate intervention 
(Fisher et al., 2010). Scores of 0-6 are considered stable, scores of 7-12 are considered 
indeterminate or possibly impending instability, and scores of 13-18 are considered 
instable (Fox et al., 2017). Surgical consultation is recommended for patients with scores 
of 7 or above (Fox et al., 2017). 
 SINS has been widely adopted in the spine oncology field, but it has yet to be 
statistically validated as accurate (Spratt et al., 2017). Part of the difficulty in examining 
the accuracy of SINS comes from the fact that SINS estimates the risk of spinal 
instability, which is technically considered a preventable event (Cassidy et al., 2018). 
Furthermore, it would be unethical to prospectively validate a spinal instability scoring 
system to document the progression of an unstable spine (Spratt et al., 2017). As a result, 
the literature has targeted interrater reliability in order to assess the validity of SINS.   
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Table 3. Spine Instability Neoplastic Score. A total score of 0-6 denotes stability; 7-12 
denotes indeterminant or impending instability; 13-18 denotes spinal instability. Table 
adapted from Fisher et al. 2010.  
 
SINS parameter Description Scoring elements Score 
Spine location This considers whether the 
location of the tumor is in a 
typically less stable spinal 
location. 
Junctional (occiput-
C2, C7-T2, T11-L1, 
L5-S1) 
3 
Mobile spine (C3-C6, 
L2-L4) 
2 
Semi-rigid (T3-T10) 1 
Rigid (S2-S5) 0 
Mechanical pain Pain relief with recumbency 
and/or pain with 
movement/upright 
posture/loading of the spine; 
this considers whether patients 
have mechanical pain 
associated with the neoplasm.  
Yes 3 
No (occasional pain 
but not mechanical) 
1 
Pain free lesion 0 
Bone lesion 
quality 
There are two types of lesions 
that result from vertebral 
metastases: lytic lesions are 
from destroyed bone material, 
and blastic lesions are from the 
bone being filled with too 
many cells.  
Lytic 2 
Mixed (lytic/blastic) 1 
Blastic 0 
Spinal alignment Subluxation, or the 
misalignment of the vertebrae, 
denotes the highest 
contribution to instability in 




De novo deformity 
(kyphosis/scoliosis) 
2 
Normal alignment 0 
Vertebral body 
collapse 
Anterior and middle column 
involvement of the vertebral 
bodies by the tumor is denoted 
by this component.  
>50% involved with 
collapse 
3 
<50% involved with 
collapse 
2 
No collapse with 
>50% vertebral body 
involvement 
1 






Posterior involvement of 
pedicles, facets, and/or 
costovertebral joints.  
Bilateral 3 
Unilateral 1 
None of the above 0 
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When the SINS performance was initially tested by members of the SOSG that 
helped create it, they reported high sensitivity and specificity, as well as near perfect 
interobserver and intraobserver reliability for differentiating the clinical categories of 
stability (Fourney et al., 2011). Additionally, Fisher et al. assessed the interobserver and 
intraobserver reliability of the three clinical categories of the SINS score (i.e. stable, 
potentially unstable, unstable) among spine surgeons and radiation oncologists. Since 
surgical consultation is recommended for patients with a SINS score of 7 or above, the 
authors also assessed agreement for a binary scale that categorized levels of stability as 
stable for SINS scores of 1-6 and “current or potential instability” for scores of 7-18. 
They found moderate interobserver agreement and substantial intraobserver agreement 
for the three clinical categories among radiation oncologists. For agreement of the binary 
scale categories, they found substantial interobserver agreement and excellent 
intraobserver agreement. The favorable agreement found for the binary scale categories is 
especially encouraging since it is a more clinically relevant than the total score alone. The 
researchers also found substantial agreement between spine surgeons and radiation 
oncologists, but cautioned that 14% of cases rated stable by the surgeons were considered 
potentially unstable by the radiation oncologists. Overall, their findings represent 
adequate reliability in using the SINS score to facilitate appropriate surgical referral.  
 Similar results have been reported throughout the literature. Arana et al. examined 
the use of SINS by 132 clinicians using a database of 90 patients, and concluded that the 
SINS score has consistent reliability between different specialties. However, Teixeira et 
al. found decreased agreement for clinicians with limited experience with spinal 
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metastases. Diagnosing and predicting risk for spinal instability is considerably 
challenging since it is not a direct physical finding on imaging, but rather a clinical 
determination that requires a certain level of multidisciplinary clinical judgement. In 
order to assess the reliability of the SINS score in less experienced clinicians, Fox et al. 
investigated agreement among spine fellows and residents in neurosurgery and 
orthopedic surgery. They found near perfect interobserver and intraobserver agreement 
among trainees, and concluded that SINS is a reliable tool that can be used as an 
educational tool for training clinicians.   
 One of the greatest strengths of the SINS scoring system is the inclusion of pain 
as a parameter for prognostication, as it is one of the only scoring systems that can be 
used in the NOMS framework that incorporates pain as an indicative clinical symptom 
(Tokuhashi et al., 2017). Pain is one of the earliest presenting indications for surgical 
consult, but imaging findings don’t necessarily correlate with patient symptoms such as 
pain. Recently, Hussain et al. found a statistically significant positive correlation between 
increasing preoperative SINS scores and patient reported severity of preoperative pain. 
The correlation between SINS scores and pain severity validates SINS as a valuable tool 
for diagnosing spinal instability and ensuring that patient’s clinical symptoms are 







Systemic Disease Assessment 
 The systemic disease assessment determines what a patient can tolerate 
physiologically, and is dependent on the extent of tumor dissemination, medical 
comorbidities, and tumor histology (Laufer et al., 2013). All treatment decisions are 
predicated on the patient’s ability to tolerate the proposed intervention, which is 
especially important for patients with spinal tumor metastases as they generally are 
already in the latter stages of metastatic disease and typically require palliative care. The 
prognosis of patients with secondary spinal tumors varies widely, and their general 
condition exerts a greater effect on prognosis than their local condition in the spine 
(Tokuhashi et al., 2017). This makes the evaluation of disease severity or prediction of 
outcome especially challenging with imaging of the local condition alone. Factors that 
influence predicted life expectancy, such as cancer type and stage, and risk for 
postoperative complications due to comorbidities are essential considerations to 
determine if the proposed treatment can be administered with acceptable risk to the 
patient. Life expectancy or predicted quality of life for patients with advanced metastatic 
disease can influence the value of surgical treatments and indicate a more palliative 
approach in some patients. 
Streamlined prognostication is imperative for adequate, patient-specific treatment 
planning because the consequences of metastatic spinal tumors can require emergent 
treatment. Prognostication scoring algorithms are available to assist physicians in 
assessing systemic disease and developing accurate prognoses. Various scoring systems 
have been developed over the past few decades, and their utility and reliability have been 
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extensively reviewed in the literature. This thesis will now evaluate the three most 
commonly cited scoring systems around the world: Tokuhashi, Tomita, and Bauer.  
 In 1989, Tokuhashi et al. created the Tokuhashi prognostic score, which evaluates 
the life expectancy and prognosis in patients with secondary spine metastases. It has been 
described in clinical studies as a valuable tool to determine the indications for treatment 
before surgery (Pelegrini de Almeida et al., 2018), and it is perhaps the most widely 
recognized scoring system for spinal metastases (Cassidy et al., 2018). Table 4a displays 
the six parameters used to evaluate metastatic spine tumors in the original score 
developed in 1989. The scoring system has since been revised in 2005 to improve its 
accuracy and prognostic value. The revised score (Table 4b) retains the original 6 
components, but the maximum score was changed from 12 to 15 to incorporate 3 new 
facets to the “primary site of the cancer” parameter of the score (Tokuhashi et al., 2005). 
In the revised system, a score of 8 or lower predicts a life expectancy of under six 
months, a score of 9-11 predicts survival for 6 months to one year, and a score of 12 or 
above predicts survival for 1 year or longer.  
 The external validity of the revised Tokuhashi score has been extensively 
examined in the literature, and Table 5 includes a summary of more recent studies that 
have examined its prognostic performance. The overall literature has been inconsistent 
with regard to the prognostic accuracy and general usefulness of the score. Tokuhashi et 
al. originally reported that the predicted life expectancy was consistent with the actual 
survival period after treatment in 86.4% of an 118 patient sample size. The predictive 
accuracy reported by the studies found in Table 5 ranged from 51% to 88%, with some 
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investigators concluding it to be a suboptimal predictor while others concluded it to be 
useful (Cassidy et al., 2018). Aoude et al., analyzed the individual parameters used in the  
Table 4. Tokuhashi scoring system. (A) The original Tokuhashi scoring system 
developed in 1989 and published in 1990. Table taken from Tokuhashi et al. 1990. (B) 
The revised Tokuhashi scoring system published in 2005 with a total possible score of 





revised Tokuhashi score in a retrospective review of 128 patients treated for spinal 
metastases. While they found that the total score was significantly associated with actual 
survival time, not all individual parameters were significantly associated with survival. 
Multivariate statistical analysis showed that only the number of spinal metastases and 
metastases to major organs were statistically significant for predicting survival.  The 
researchers also conducted univariate analysis for each parameter, and all had statistically 
significant associations with survival except for “primary site of the cancer.” These 
conflicting results suggest that the individual parameters used to calculate the Tokuhashi 
score have variable utility as predictors, which leaves room modifications to improve the 
score’s overall accuracy. Their results also propose that the quantity of metastases to the 
spine and other organs has a higher association with survival, regardless of the primary 
tumor type. Most patients with spinal metastases have a poor prognosis simply due to 
their advanced cancer status irrespective of primary tumor location. The Tokuhashi score 
fails to account for the stage of malignancy in the “primary site of the cancer” element, 
which may contribute to the discordant findings of studies with different sample 
populations.   
The inconsistencies reported in the literature make it difficult to determine the 
actual prognostic value of the revised Tokuhashi system, which has negative implications 
for its reliability to help develop treatment plans. Tokuhashi et al. suggested that patients 
with low scores, and therefore short predicted life expectancies, should be recommended 
for more palliative treatment rather than surgery. However, recent studies have found that 
patients with lower scores that are referred for surgery actually had better outcomes. In a  
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Table 5. Studies that have examined the prognostic performance of the revised 
Tokuhashi scoring system. Table adapted from Cassidy et al. 2018. 
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study of patients that underwent spinal cord decompression surgery due to spinal 
metastases, patients with lower scores survived longer after surgery than the Tokuhashi 
system predicted (Pelegrini de Almeida et al., 2018). Luis Mattana et al. similarly showed 
that patients with low scores that underwent surgical treatments lived longer than the 
patients reported by Tokuhashi that were not operated on. Importantly, both studies 
compared their results to the results originally reported by Tokuhashi, but they did not 
account for advances in cancer treatments that have been developed after the revised 
Tokuhashi score was published in 2005.  
Cancer therapeutics have been revolutionized since then, increasing the life 
expectancy for cancer patients. This, in fact, is a major flaw of the Tokuhashi score, as it 
does not take the effectiveness of new therapeutic strategies into consideration, 
contributing to a progressive loss of accuracy as new, more-effective treatments become 
available (Zoccali et al., 2016). Schmidt Morgen et al. attempted to create their own 
revised form of the Tokuhashi score to account for the improved survival among cancer 
patients. Their preliminary analysis determined that the “extra spinal bone metastases” 
variable had limited prognostic value in predicting survival. They noted that information 
regarding metastases to major internal organs and extra spinal bones was insufficient in 
most patients at the time of admission, and 20% of the patients they studied had an 
unknown primary cancer with no evaluation of extra spinal tumors. After omitting the 
“extra spinal bone metastases” variable and altering the score values for the “primary site 
of the cancer” variable, their modified score had significantly better survival prediction 
accuracy in both surgically treated and non-surgically treated patients. There is still room 
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for improvement, however, as severe pain is one of the main reasons for treatment, but 
pain is not incorporated into the scoring system. Additionally, there are no parameters for 
quality of life or the patient’s treatment preference, which highlights how scoring systems 
should not be used as stand alone treatment decision makers (Schmidt Morgen et al., 
2018).  
In 2001, Tomita et al. developed their own scoring system by retrospectively 
analyzing the predictive value of prognostic factors in 67 patients that underwent 
treatment for spinal metastases at their institution. They produced a 3-parameter scoring 
system with corresponding treatment proposals, shown in Table 6. The points assigned to 
each of the 3 parameters were weighted based on the prognostic importance determined 
by their retrospective analysis of prognostic factors. Multiple studies have reported 
significant associations between survival and the Tomita score, and some authors have 
favored it due to its user friendly design and inclusion of primary tumor histology as a  
 
Table 6. The Tomita scoring system. Table taken from Tokuhashi et al. 2017. 
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prognostic factor (Cassidy et al., 2018). In contrast, other studies have determined the 
score to have suboptimal reliability when predicting survival, and inaccuracies that hinder 
its ability to inform on treatment plans. The treatment proposals made by Tomita et al. 
were based on a 7-category anatomical classification method, shown in Figure 7. 
However, this classification system is not necessarily useful since the intra-
compartmental types 1-3 are clinically the same category, and the anatomical 
classifications are not necessarily correlated with life expectancy (Tokuhashi et al., 
2017). The Tomita score has also been criticized for overlooking paralysis as an 
important factor for poor prognosis (Alapantaki et al., 2020).  




To assess the reliability of the Tomita scoring system in clinical practice, Arana et 
al. evaluated agreement in the calculation of the score across various relevant specialties. 
They found that both intraobserver agreement and interobserver agreement were “almost 
perfect” in the calculation of the Tomita score across all participating specialties and 
experience levels. While this suggests that the system is intrinsically reliable, prognostic 
agreement does not ensure that the predicted life expectancy will be accurate, or that the 
recommended treatment is the most appropriate. Ahmed et al. found that the Tomita 
score accurately predicted 365-day survival after surgery, but that it was not accurate in 
predicting 30 or 90 day survival. On the other hand, another study demonstrated that both 
the Tokuhashi and Tomita score were accurate in predicting poor prognosis (survival less 
than 6 months), but that the Tomita score was limited in distinguishing between moderate 
(6 to 12 months) and good (over 12 months) prognosis for patients undergoing surgery 
for spine metastases (Aoude et al., 2014). The Tomita score also failed to significantly 
differentiate between the proposed good and moderate prognosis subgroups in a study by 
Dardic et al. The Tomita score is therefore questionable as a prognostic indicator for 
treatment plans, but certain aspects of the scoring method—such as its accessibility and 
inclusion of anatomical factors—are still valuable to consider for inclusion in other 
scoring algorithms. 
While Arana et al., found the Tomita score to have better agreement than the 
modified Bauer score, previous studies have shown that the modified Bauer scoring 
system is simpler and predicts survival better than the Tomita one (Wibmer et al, 2011). 
Bauer et al. originally developed a scoring system in 1995 based on data from 153 
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patients with limb bone metastases and 88 patients with spinal involvements. It was 
designed to address not only spinal metastases, but extremity metastases as well. They 
proposed a relatively simple single point system of 5 prognostic criteria: absence of 
visceral metastases, absence of pathological fracture, solitary skeletal metastasis, not 
primary lung cancer, and primary tumor is breast, kidney, lymphoma or myeloma. They 
reported that the 1-year survival rate was 0% for patients with scores of 0-1, 25% for 
patients with scores of 2-3, and 50% for those with scored of 4-5. All patients with scores 
of 0-1died within six months.  
The original Bauer publication noted that it was difficult to evaluate the presence 
or absence of pathological fractures by imaging, and that the impact of pathological 
fracture was only evident in patients with extremity metastases. As a result, Leithner et 
al., proposed a modified Bauer score that excluded scoring for pathological fractures, 
shown in Table 7. After analyzing 7 different preoperative scoring systems for spinal 
metastases, Leithner et al. reported that the modified Bauer score had the best correlation 
with survival. Similar findings have been reported in at least two other studies comparing 
different prognostic systems. Dardic et al., found that both the original Bauer and 
modified Bauer scores had significant results in distinguishing between proposed 
prognostic subgroups, and they showed the strongest impact on predicting survival. They 
were also the least influenced by different patient collectives, such as varying age, 
gender, and primary tumor distribution. Wimber et al., found that both Bauer scoring 
systems were able to significantly distinguish between the three prognosis groups they 
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proposed, and concluded that the modified Bauer score provided the most reliable life 
expectancy results to help determine surgical indications.   
 
Table 7. The modified Bauer scoring system. The score and proposed interpretations 
were developed by Leithner et al. Table taken from Cassidy et al. 2018. 
 
 
Though it has been praised for its simplicity, the modified Bauer score only 
recognizes 4 primary cancer types within its calculation, and has broad survival 
categories that likely contain a large spectrum of different prognoses within the 
subgroups (Cassidy et al., 2018). This may allow the modified Bauer score to be more 
statically precise than it is clinically useful. The modified Bauer score provides median 
overall survival times for their three prognostic subgroups, and recommends excisional 
surgery via antero-posterior combined approach for scores of 3-4, posterior palliative 
surgery for scores of 2, and no surgery for scores of 0-1. However, the wide range of 
survival times around each median overall survival given for each subgroup may require 
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patients within 1 subgroup to have variable surgical implications. Other studies have 
shown that the Bauer scores are not accurate in predicting survival within specifically 
delineated time intervals (ie. 1 month, 3 month and 1 year survival) (Ahmed et al., 2018). 
Interestingly, the original and modified Bauer scores are the only ones to include 
lymphoma and multiple myeloma in their classification, although spinal lesions of 
multiple myeloma and lymphoma are not considered metastases (Ahmed et al., 2018). 
Some authors have also criticized the modified Bauer score for failing to consider general 
health and nutritional status of patients (Ghori et al., 2015). Ghori et al. further refined 
the modified Bauer score to include preoperative ambulatory status to represent the 
patient’s functional state, and serum albumin to represent nutritional status. They 
reported that including these as prognostic factors improved the accuracy of the score 
from 64% to 74%. Goodwin et al. subsequently examined the accuracy of this 
modification in their own study, and found 80% accuracy in their cohort. There is clearly 
still room for improvement to include a more holistic representation of patients’ health 
status for better prognostication in all scoring systems discussed thus far. 










 Developing treatment protocols for patients with spinal tumor metastases requires 
an interdisciplinary approach, with input from radiologist, surgeons and oncologists. The 
NOMS decision-making framework is a major advancement towards standardizing 
treatment protocols in a patient-specific manner. It has already been widely adopted 
throughout the literature, and it is generally portrayed favorably by reviews. Despite the 
positivity expressed by investigators, there are essentially no statistical evaluations of the 
usefulness of NOMS in real clinical settings. Prospective research on NOMS would 
likely be unethical, but retrospective reviews of patient outcomes after being treated 
using the NOMS framework would be a helpful starting point for future research.  
Effective treatment is predicated on accurate and early diagnosis. MRI is the 
current standard for spinal imaging of metastatic disease, partly because it is the most 
accessible imaging method available at present. MRI techniques vary by institution, and 
imaging analysis typically relies on clinical judgement based on experience. Scoring 
algorithms such as the META score can be a useful tool for physicians of all clinical 
experience levels to assist in diagnosing metastatic spinal disease by creating a 
framework for identifying key MRI findings. However, while there is clearly need for an 
accurate and quantifiable way to better diagnose spinal metastases, the current literature 
suggests that the available prediction models are not reliable enough to be used in a real 
clinical setting with patients yet to be diagnosed. The severity of the consequences for 
patients with spinal tumor metastases that are misdiagnosed, or delayed being diagnosed, 
requires prediction models to be significantly more accurate before they can be put to 
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practice in a clinical setting. In order to successfully develop such a model, more larger 
scale research should be done on both prediction algorithms and the MRI image 
predictors themselves. While the findings that clinicians look for to diagnose spinal 
tumor metastases or metastatic vertebral fractures are relatively standard, their usefulness 
as objective predictors in an algorithmic model may not be equally reliable in different 
clinical settings. 
 One of the integral aspects of NOMS that has been praised in the literature is the 
fact that it is dynamic and able to incorporate new findings as more research is published. 
The ability to be easily updated based on the most recent clinical findings is something 
that the individual scoring systems used within NOMS lack. While some scoring systems 
have been revised after their initial publication, they are not modified frequently enough 
to prevent them from becoming outdated. In addition, the literature assessments of the 
reliability and validity of most of the scoring systems discussed has been conflicting. In 
practice, the use of rigid survival prediction systems, such as the Tokuhashi, Tomita and 
Bauer scores, is cautioned in favor of individualized conversations with oncologists. All 
of the scoring algorithms discussed in this thesis cannot presently be used alone to make 
definitive prognostic decisions and still require input from experienced clinicians. Future 
research on prognostic scoring systems should focus on assessing the true reliability of 
these algorithms, as well as ways to improve their overall validity in clinical settings. The 
ESCC score and SINS score seem to be better designed scoring systems and are more 
widely used than the other prognostic scoring systems. The literature describes the ESCC 
score as reliable, but it is still limited in its ability to assist in treatment planning since it 
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does not include more specific parameters about the location of tumors in the spine. SINS 
is also generally favored by the literature, but more outcomes research on its reliability is 
still needed. Future studies that evaluate the SINS score should also be designed to more 
accurately represent the clinical settings it would be used in, as many of the literature 
assessments used the creators of the SINS algorithm to test it and did not provide them 
with full patient histories that physicians in practice would have to distill for the most 
relevant information.  
 
CONCLUSION 
 This thesis has determined that standardized prognostication and treatment 
planning has high potential for improving treatment outcomes, but more research on their 
accuracy is imperative for their optimal application. Creating a common language across 
medical disciplines can help streamline the treatment process and prevent unnecessary 
complications. As the revolutionary advancements in cancer treatment continue to unfold 
and more cancer patients achieve long term survival, the incidence of spinal tumor 
metastases will increase for patients with advanced metastatic cancers. It is critical for the 
spine oncology field to continue to prepare for the patients of the future so that treatment 
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